

PERSONAL INFORMATION Jeffrey Yachnin

WORK EXPERIENCE

-
- 2017–Present **Section Head Phase I Unit**
Center for Clinical Cancer Studies, Karolinska University Hospital (Sweden)
- 2011–2017 **Director Clinical Trials Unit**
Department of Oncology, Karolinska University Hospital (Sweden)
- 2008–2011 **Medical Director**
Clinical Trials Unit, Department of Oncology, University Hospital, Uppsala (Sweden)
- 2006–2011 **Senior Staff Physician**
Department of Oncology, University Hospital, Uppsala (Sweden)
- 2000–2011 **Consultant Oncologist**
Miilar Hospital, Eskilstuna (Sweden)
- 1999–2006 **Staff Physician**
Radiumhemmet, Karolinska Hospital (Sweden)
- 1995–1999 **Resident, Department of Oncology**
Radiumhemmet, Karolinska Hospital (Sweden)
- 1993–1995 **Resident, Department of Respiratory Medicine**
Karolinska Hospital, Stockholm (Sweden)
- 1992–1993 **Internship**
Danderyds Hospital, Danderyd (Sweden)
- 1991–1991 **Staff physician**
Emergency Medicine, Charles S. Curtis Hospital (Canada)
- 1990–1991 **Resident**
Department of Family Medicine, McGill University (Canada)
- 1989–1990 **Residen**
Department of Internal Medicine, Eksjo Hospital (Sweden)
- 1988–1989 **Resident**
Department of Radiology, Eksjo Hospital (Sweden)
- 1986–1987 **Internship**
Memorial University of Newfoundland (Canada)

EDUCATION AND TRAINING

- 1976–1979 **Bachelor of Science (biology)**
McGill University, Montreal (Canada)

- 1980–1986 **Bachelor of medicine**
Royal College of Surgeons in Ireland (Ireland)

- **PhD**
Karolinska Institute (Sweden)
Chemical, Pharmacokinetic and Biological Aspects of Platinum-Based Drugs

- 2003– **Completion of GCP course**
(Sweden)

- 2007– **Completion of NCI online course**
in Human Participant Protections Education for Research

- 2009– **Principal Investigator and co-investigator**

- 2013– **Completion of GCP course I PULS nr 2011 0281**

- 2016– **Completion of GCP course Transelerate**

- September 2019– **GCP course Transelerate**

 ADDITIONAL INFORMATION

Expertise

Publications

Yachnin J.R., Wallin I., Lewensohn R., Sirzen F. and H.Ehrsson, The kinetics and cytotoxicity of cisplatin and its monohydrated complex. *Cancer Lett.* 132: 175-180, 1998.

Werkii L., Lie S.O., Winberg J. and J.R. Yachnin. Report to the Paediatric Cancer Fund on an evaluation of the use of research funds in paediatric cancer in Sweden. 2000.

Eriksson A, Yachnin J.R., Lewensohn R. and A. Nilsson, DNA-Dependent Protein Kinase Is Inhibited by Trifluoperazine. *Biochem. Biophys. Res. Commun.* 283(4): 726-731, 2001.

Videhult P., Yachnin J., Jerremalm E., Lewensohn R. and H. Ehrsson, Synthesis and Cytotoxicity of the dihydrated complex of oxaliplatin, *Cancer Lett.* 180: 191-194, 2002.

Ehrsson H., Wallin I. and J. Yachnin, Pharmacokinetics of oxaliplatin in humans, *Med. Oncol.* 19(4): 261-265, 2002.

Jerremalm E., Wallin I., Yachnin J. and Ehrsson H., Oxaliplatin degradation in the presence of important biologic sulphur-containing compounds and plasma ultrafiltrate. *Eur. J. Pharm. Sci.* 28(2): 278-283, 2006.

Nilsson S., Franzen L., Parker C., Tyrrell C., Blom R., Tennvall J., Lennemlis B., Petersson U., Johannessen D.C., Sokal M., Pigott K., Yachnin J. et al Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multinational, placebo-controlled phase II study. *Lancet Oncol.* 8(7): 587-594, 2007.

Broomand A, Jerremalm E, Yachnin J, Ehrsson H, Blinder F, Oxaliplatin neurotoxicity--no general ion channel surface-charge effect. *J Negat Results Biomed.* Jan 12;8:2, 2009

Yachnin J and Enblad G., Krangel och byrakati hot mot klinisk forskning. *Likemedelsverket* 107(23):

1525- 1526, 2010.

Lehman S., Bykov V.J.N., Ali D., Andren O., Cherif H., Tidefelt U., Uggla B., Yachnin J., Juliusson G., Mosfeh A., Paul C., Wiman K.G. and Andersson P-O, Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic and Prostate Cancer; *J Clin Oncol* 30: 3633- 3639, 2012.

F. Eriksson, T. Totterman, A-K Maltais, P. Pisa and Yachnin J., DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed cancer; *Vaccine* 31(37): 3843-3848, 2013.

Pierre Maison-Blanche, Shaker Dakhil, Ari Baron, Sylvie Rottey, Fred Millard, Gedeske Daugaard, Jean-Pascal Machiels, William Conkright, Sunil Sharma, Patricia Soetkouw, Jeffrey Yachnin et al; An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors; *Cancer Chemother Pharmacol* 2014 Jun; 73(6): 1241-52.

Kharaziha P, Chioureas D, Rutishauser D, Baltatzis G, Lennartsson L, Fonseca P, Azimi A, Hultenby K, Zubarev R, Ullen A, Yachnin J et al; Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel. *Oncotarget* 2015 Aug 28;6(25): 21740-54.

Ronquist KG, Sanchez C, Dubois L., Chioureas D., Fonseca P., Larsson A., Ullen A., Yachnin J., Ronquist G., Panaretakis T., Energy-requiring uptake of prostasomes and PC3 cell-derived exosomes into non-malignant and malignant cells. *J Extracell Vesicles* 2016, mar 7; 5: 29877.

Diaz H.E., Yachnin J., Gronberg H. Lindberg J., The In Vitro Stability of Circulating Tumor DNA. *PLoS one* 2016: Dec 13 11(12): 1-16.

Yachnin J, Gilje B, Thon K, Johansson H, Brandberg Y, Panaretakis T, Ullen A; Weekly versus 3-weekly cabazitaxel for the treatment of castration-resistant prostate cancer: A randomised phase II trial (ConCab); *Eur. J. Cancer* 2018 (in press)

Mayrhofer M, De Laere B1, Whittington T, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert E, De Maeseneer D, Strijbos M, Bols A, Fransis K, Oeyen S, van Dam PJ, Van den Eynden G, Rutten A, Aly M, Nordström T, Van Laere S, Rantalainen M, Rajan P, Egevad L, Ullén A, Yachnin J, Dirix L, Grönberg H, Lindberg J., Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis; *Genome Med.* 2018 Nov 21;10(1):85.

De Laere B, Oeyen S, Mayrhofer M, Whittington T, van Dam PJ, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert EG, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff IE, van Dam V, Brouwer A, Goossens D, Heyrman L, Van den Eynden GG, Rutten A, Del Favero J, Rantalainen M, Rajan P, Sleijfer S, Ullén A, Yachnin J, Grönberg H, Van Laere SJ, Lindberg J, Dirix LY.; TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer; *Clin Cancer Res.* 2018 Sep 12. doi: 10.1158/1078-0432.CCR-18-1943

Carl-Henrik Shah, Helle Pappot, Mads Agerbaek, Karin Holmsten, Fredrik Jäderling, Jeffrey Yachnin, Per Grybäck, Hans Von Der Masse, Anders Ullén.; Safety and Activity of Sorafenib in Addition to Vinflunine in

Post-Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial; *The Oncologist* 2018;23:1–10.

de Bono Johan S, Concin N, Hong David S, Thistlethwaite Fiona C, Machiels Jean-Pascal, Arkenau Hendrik-Tobias, Plummer Ruth, Jones Robert Hugh, Nielsen Dorte, Windfeld Kristian, Ghatta Srinivas, Slomovitz Brian M, Spicer James F, Yachnin Jeffrey et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial ; *Lancet Oncol* 2019; 20: 383–93, MARCH 01, 2019

Projects

Memberships

Other Relevant Information